SCHEMBL21753199

SCHEMBL21753199

CC(C)(C)OC(=O)N1CC(CNc2ccc3c(c2)CN(C2CCC(=O)NC2=O)C3=O)C1

nearest known ligand 0.59

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 11/20 0.59
▸ CSNK1A1 P48729 6/20 0.56
▸ IKZF2 Q9UKS7 12/20 0.53
▸ DDB1 Q16531 2/20 0.51
▸ GSPT1 P15170 1/20 0.49
▸ IKZF3 Q9UKT9 1/20 0.49
▸ GPR119 Q8TDV5 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32660167 1.00 CRBN (0.59) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL21753143 0.93 CRBN (0.59) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL31554630 0.93 CRBN (0.59) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL21760140 0.87 IKZF2 (0.59) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL20234406 0.87 CRBN (0.62) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL28881307 0.87 CRBN (0.59) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL20442568 0.86 GPR119 (0.67) CRBNCSNK1A1IKZF2DDB1GPR119
SCHEMBL25581068 0.86 CRBN (0.54) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL29126556 0.85 CRBN (0.61) CRBNCSNK1A1IKZF2DDB1GSPT1
SCHEMBL30341653 0.85 CRBN (0.61) CRBNCSNK1A1IKZF2DDB1GSPT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388587-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN SHANGHAI INC (CN) 2025-12-25 — — US disclosed
US-11969472-B2 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use CULLGEN (SHANGHAI), INC. (CN) 2024-04-30 — — US disclosed
CN-115626927-B Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use 上海睿跃生物科技有限公司 2024-01-02 — — CN disclosed
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2023-08-17 — — US disclosed
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2023-08-17 — — US disclosed
CN-115697989-A Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use 上海睿跃生物科技有限公司 2023-02-03 — — CN disclosed
CN-115626927-A Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use 上海睿跃生物科技有限公司 2023-01-20 — — CN disclosed
EP-4110772-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE Cullgen (Shanghai), Inc. (CN) 2023-01-04 — — EP disclosed
US-20210363146-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2021-11-25 — — US disclosed
US-20210315999-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2021-10-14 — — US disclosed
US-20210315999-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2021-10-14 — — US disclosed
EP-3841098-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE Cullgen (Shanghai), Inc. (CN) 2021-06-30 — — EP disclosed
CN-112888681-A Tropomyosin Receptor Kinase (TRK) degrading compounds and methods of use 上海睿跃生物科技有限公司 2021-06-01 — — CN disclosed
WO-2020038415-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2020-02-27 — — WO disclosed
WO-2020038415-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2020-02-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, ERBB2, NTRK1 CRBN 330/4885CSNK1A1 62/4885IKZF2 2170/4885
US-11969472-B2 Tropomyosin receptor kinase (TRK) degradation compounds and methods of use MUSK, ERBB2, NTRK1 CRBN 330/4885CSNK1A1 62/4885IKZF2 2170/4885
US-20250388587-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE ERBB2, MUSK, ERBB3 CRBN 149/4885CSNK1A1 23/4885IKZF2 2290/4885
US-20210363146-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, NTRK1, ERBB2 CRBN 194/4885CSNK1A1 48/4885IKZF2 1536/4885
US-20210315999-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, ERBB2, NTRK1 CRBN 330/4885CSNK1A1 62/4885IKZF2 2170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback